Radiopharm Theranostics Raises A$40M to Propel Clinical Trials Forward

• A$35 million placement at $0.03 per share to institutional and sophisticated investors
• Strategic investor Lantheus increases stake to 14.5% with A$7.6 million investment
• A$5 million Share Purchase Plan offered to existing eligible shareholders
• One free attaching option per new share, exercisable at $0.039 until October 2027